Should I buy Collegium Pharmaceutical, Inc. (COLL) stock or is it too late?

Collegium Pharmaceutical, Inc. · Health Care · price $22

See the full Collegium Pharmaceutical, Inc. (COLL) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Leerink Partners — 64% of its targets hit on this sector (11 calls tested). It aims for $45 (+109 %), call made on September 10, 2026, maturing on September 10, 2027 (34 d ago).

The 1 reliable analyst $45+109 %

The 5 other firms $48+123 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $45 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Collegium Pharmaceutical, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Needham	71 %	+20.6 %	21	$46 +114%
HC Wainwright & Co.	56 %	+10.2 %	9	$60 +179%

In short — Should you invest in Collegium Pharmaceutical, Inc.? Is it too late, still worth it? Analysts are overwhelmingly positive (83% buy, median target $47, i.e. +118%), and the most reliable on COLL targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

83% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
Median price target $47, i.e. +118% from the current price ($22).
The most reliable firm on COLL, Needham (71% hit rate, 21 scored calls), targets $46 (call made on August 6, 2026, maturing on August 6, 2027) (+114%) in its most recent call, and $46 (call made on October 28, 2025, maturing on October 28, 2026) (+114%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 6 ratings, 1 is neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on COLL

Median target $47 (+118%) · 6 ratings · Buy consensus

Strong Buy00%

Buy583%

Hold117%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Collegium Pharmaceutical, Inc. now?

We won't decide for you. The facts: 83% of analysts rate it a buy, median target $47 (+118%), and Needham (most reliable on COLL, 71%) targets $46. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Collegium Pharmaceutical, Inc.?

Not according to analysts: the median target ($47) is still +118% above the current price ($22) (most reliable on COLL: Needham, 71%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Collegium Pharmaceutical, Inc. still worth investing in?

It depends on the gap between the price ($22) and its estimated value: analysts target $47 on median (+118%), with 83% buys (most reliable on COLL: Needham, 71%). Cross-check with their real reliability on COLL and the cautions above. Information, not advice.

What's the main risk in buying COLL?

The consensus is not unanimous: of 6 ratings, 1 is neutral.

→ Go deeper: the full Collegium Pharmaceutical, Inc. profile (consensus, analyst reliability, price target, performance).